Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves’ disease-Reference-Cited by-同舟云学术

Thyrotrophin receptor antibody concentration and activity, several years after treatment for Graves’ disease

Published:2018-12-17 Issue:2 Volume:90 Page:369-374
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Nalla Preethi¹,Young Stuart²,Sanders Jane²,Carter Joanne¹,Adlan Mohamed A.¹,Kabelis Katarzyna²,Chen Shu²,Furmaniak Jadwiga²,Rees Smith Bernard²,Premawardhana Lakdasa D. K. E.¹^ORCID

Affiliation:

1. Section of Endocrinology and BiochemistryAneurin Bevan University Health Board Caerphilly UK

2. FIRS LaboratoriesRSR Ltd. Cardiff UK

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cen.13908

Reference25 articles.

1. Graves’ Disease

2. Measuring TSH receptor antibody to influence treatment choices in Graves’ disease

3. Clinical Utility of TSH Receptor Antibodies

4. Graves' Ophthalmopathy

5. Performance and Specificity of 6 Immunoassays for TSH Receptor Antibodies: A Multicenter Study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Percutaneous triamcinolone injection for upper eyelid retraction in thyroid eye disease;Frontiers in Ophthalmology;2024-05-17

2. Increased interleukin-9 and Th9 cells in patients with refractory Graves’ disease and interleukin-9 polymorphisms are associated with autoimmune thyroid diseases;Frontiers in Immunology;2024-03-28

3. Analysis of Related Factors in Refractory Graves’ Disease;Advances in Clinical Medicine;2023

4. Changes in Th9 and Th17 lymphocytes and functional cytokines and their relationship with thyroid-stimulating hormone receptor antibodies at different stages of graves’ disease;Frontiers in Immunology;2022-07-22

5. TSH receptor specific monoclonal autoantibody K1‐70 ^TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial;Clinical Endocrinology;2022-02-06